Atsuto Mouri

1.0k total citations
72 papers, 677 citations indexed

About

Atsuto Mouri is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Atsuto Mouri has authored 72 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 9 papers in Epidemiology. Recurrent topics in Atsuto Mouri's work include Lung Cancer Treatments and Mutations (31 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Atsuto Mouri is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Diagnosis and Treatment (14 papers). Atsuto Mouri collaborates with scholars based in Japan, Nepal and United Kingdom. Atsuto Mouri's co-authors include Hiroshi Kagamu, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kunihiko Kobayashi, Yu Miura, Kosuke Hashimoto, Yoshitake Murayama, Fuyumi Nishihara and Hisao Imai and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Atsuto Mouri

67 papers receiving 676 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atsuto Mouri Japan 16 520 385 86 72 58 72 677
Ayako Shiono Japan 15 605 1.2× 389 1.0× 185 2.2× 71 1.0× 78 1.3× 59 783
Xiao-Jing Du China 8 497 1.0× 194 0.5× 103 1.2× 46 0.6× 44 0.8× 9 677
Hirotaka Ono Japan 8 449 0.9× 264 0.7× 100 1.2× 30 0.4× 94 1.6× 23 601
Munehiro Ito Japan 8 481 0.9× 317 0.8× 81 0.9× 25 0.3× 28 0.5× 14 541
Luc Thiberville France 11 427 0.8× 597 1.6× 84 1.0× 35 0.5× 102 1.8× 35 856
Hayato Kawachi Japan 12 549 1.1× 435 1.1× 88 1.0× 40 0.6× 46 0.8× 35 711
Nobuaki Mamesaya Japan 16 417 0.8× 385 1.0× 21 0.2× 32 0.4× 66 1.1× 61 579
Naoko Imanishi Japan 15 236 0.5× 487 1.3× 36 0.4× 33 0.5× 38 0.7× 64 669
Shota Omori Japan 20 648 1.2× 671 1.7× 37 0.4× 60 0.8× 90 1.6× 81 976
Nicolás Moreno‐Mata Spain 15 150 0.3× 259 0.7× 39 0.5× 50 0.7× 87 1.5× 56 514

Countries citing papers authored by Atsuto Mouri

Since Specialization
Citations

This map shows the geographic impact of Atsuto Mouri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsuto Mouri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsuto Mouri more than expected).

Fields of papers citing papers by Atsuto Mouri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsuto Mouri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsuto Mouri. The network helps show where Atsuto Mouri may publish in the future.

Co-authorship network of co-authors of Atsuto Mouri

This figure shows the co-authorship network connecting the top 25 collaborators of Atsuto Mouri. A scholar is included among the top collaborators of Atsuto Mouri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsuto Mouri. Atsuto Mouri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Uchida, Takahiro, Kazuyuki Nakagome, Kosuke Hashimoto, et al.. (2025). Eosinophils as predictive biomarkers in anti-programmed cell death 1 monotherapy for non-small cell lung cancer. Frontiers in Immunology. 16. 1574314–1574314. 1 indexed citations
2.
Imai, Hisao, Ayako Shiono, Kosuke Hashimoto, et al.. (2025). Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer. Anticancer Research. 45(2). 733–741. 1 indexed citations
3.
Endo, Satoshi, Hisao Imai, Atsuto Mouri, et al.. (2025). Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 151(1). 43–43. 2 indexed citations
4.
Kaira, Kyoichi, Hisao Imai, Ayako Shiono, et al.. (2025). Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy. Translational Lung Cancer Research. 14(5). 1569–1581. 1 indexed citations
5.
6.
Ito, Koki, Kyoichi Kaira, Ou Yamaguchi, et al.. (2024). Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. Oncology Letters. 27(3). 110–110. 4 indexed citations
7.
Hayashi, Hidetoshi, Makoto Nishio, Hiroaki Akamatsu, et al.. (2024). Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. Cancer Research Communications. 4(11). 2858–2867. 2 indexed citations
8.
9.
Hashimoto, Kosuke, Kyoichi Kaira, Hisao Imai, et al.. (2024). Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer. Cancer Imaging. 24(1). 157–157. 1 indexed citations
10.
11.
Kaira, Kyoichi, Hisao Imai, Atsuto Mouri, et al.. (2023). Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib. Thoracic Cancer. 14(29). 2950–2961. 3 indexed citations
12.
Kaira, Kyoichi, Ou Yamaguchi, Tomonori Kawasaki, et al.. (2023). Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. Discover Oncology. 14(1). 6–6. 16 indexed citations
13.
Kagamu, Hiroshi, Shigehisa Kitano, Ou Yamaguchi, et al.. (2022). Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy. Cancer Research. 82(24). 4641–4653. 27 indexed citations
14.
Mouri, Atsuto, Kyoichi Kaira, Ou Yamaguchi, et al.. (2021). Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology. 11. 610952–610952. 11 indexed citations
15.
Imai, Hisao, Ou Yamaguchi, Kosuke Hashimoto, et al.. (2021). Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. Chemotherapy. 66(3). 65–71. 4 indexed citations
16.
17.
Yamaguchi, Ou, Kyoichi Kaira, Kosuke Hashimoto, et al.. (2020). Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%. Scientific Reports. 10(1). 14990–14990. 24 indexed citations
18.
Yamaguchi, Ou, Kyoichi Kaira, Atsuto Mouri, et al.. (2019). Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology. 83(5). 817–825. 12 indexed citations
19.
Kamimura, Mitsuhiro, et al.. (2017). A new method for enhanced expectoration of sputum by vibratory stimulation of the cervical trachea. Respiratory Investigation. 55(4). 276–282. 1 indexed citations
20.
Kamimura, Mitsuhiro, et al.. (2010). Cough challenge tests involving mechanical stimulation of the cervical trachea in patients with cough as a leading symptom. Respirology. 15(8). 1244–1251. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ayako Shiono Breakdown of academic impact, for papers by Xiao-Jing Du Breakdown of academic impact, for papers by Hirotaka Ono Breakdown of academic impact, for papers by Munehiro Ito Breakdown of academic impact, for papers by Luc Thiberville Breakdown of academic impact, for papers by Hayato Kawachi Breakdown of academic impact, for papers by Nobuaki Mamesaya Breakdown of academic impact, for papers by Naoko Imanishi Breakdown of academic impact, for papers by Shota Omori Breakdown of academic impact, for papers by Nicolás Moreno‐Mata
Rankless by CCL
2026